Researchers in South Korea have proposed a novel cancer immunotherapy approach ... in the journal Biomarker Research. B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly ...

A study has demonstrated the potential of a novel ligand-based CAR T-cell therapy for targeting CD7-positive T-cell malignancies, including T-cell acute lymphoblastic leukemia (T-ALL) and T-cell ...

Detailed price information for Sellas Life Sciences Group Inc (SLS-Q) from The Globe and Mail including charting and trades.

ADC Therapeutics SA (NYSE: ADCT) Q1 2025 Earnings Call Transcript May 14, 2025 ADC Therapeutics SA beats earnings ...

Second of 2 parts featuring an interview with Stephen Strickland, MD, MSCI,director, Leukemia Research for Sarah Cannon ...

One of the first truly targeted cancer agents, Glivec has transformed outcomes for patients with chronic myeloid leukaemia (CML) and acute lymphocytic leukaemia (ALL). A landmark clinical trial in ...

Then, we have MDS, secondary myeloid neoplasms, and acute myeloid leukemia ... Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia ...

Acute lymphocytic leukaemia (ALL) is a cancer of the blood and bone marrow, specifically affecting lymphocytes. The disease progresses rapidly and creates immature blood cells, rather than mature ...

Swedish cancer patients treated with CAR T-cell therapy show better survival rates and fewer side effects than seen in ...